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ABSTRACT  
We generated transmitochondrial mice (mito-mice) that carry a mutation in the tRNALys 
gene encoded by mitochondrial DNA (mtDNA) for use in studies of its pathogenesis 
and transmission profiles. Because patients with mitochondrial diseases frequently carry 
mutations in the mitochondrial tRNALys and tRNALeu(UUR) genes, we focused our efforts 
on identifying somatic mutations of these genes in mouse lung carcinoma P29 cells. Of 
the 43 clones of PCR products including the tRNALys or tRNALeu(UUR) genes in mtDNA 
of P29 cells, one had a potentially pathogenic mutation (G7731A) in the tRNALys gene. 
P29 subclones with predominant amounts of G7731A mtDNA expressed respiration 
defects, thus suggesting the pathogenicity of this mutation. We then transferred G7731A 
mtDNA into mouse ES cells and obtained F0 chimeric mice. Mating these F0 mice with 
C57BL/6J (B6) male mice resulted in the generation of F1 mice with G7731A mtDNA, 
named ‘mito-mice-tRNALys7731’. Maternal inheritance and random segregation of 
G7731A mtDNA occurred in subsequent generations. Mito-mice-tRNALys7731 with high 
proportions of G7731A mtDNA exclusively expressed respiration defects and disease-
related phenotypes, and therefore are potential models for mitochondrial diseases due to 
mutations in the mitochondrial tRNALys gene. Moreover, the proportion of mutated 
mtDNA varied markedly among the pups born to each dam, suggesting that selecting 
oocytes with high proportions of normal mtDNA from affected mothers with tRNALys-
based mitochondrial diseases may be effective as primary prevention for obtaining 
unaffected children.  
Keywords: mouse mtDNA mutation; mitochondrial tRNALys gene; transmitochondrial 
mice; mutated mtDNA segregation; primary prevention 
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Significance statement 
We generated transmitochondrial mito-mice-tRNALys7731 as models for precise 
examination of the pathogenesis and transmission profiles of mtDNA mutations in the 
tRNALys genes, and have obtained important information regarding primary prevention 
of the diseases caused by the mtDNA mutations. Although nuclear transplantation from 
oocytes of affected mothers into enucleated oocytes of unrelated women has been 
suggested, the methodology carries the technical risk of inducing nuclear abnormalities 
and prompts ethical concerns regarding the production of three-parent babies with 
normal mtDNA from unrelated oocyte donors. The current study suggests that the 
selection of oocytes with high proportions of normal mtDNA from affected mothers can 
be used to avoid these issues and therefore provides new insights into mitochondrial 
genetics and medicine. 
\body 
Introduction 
Mitochondrial DNA (mtDNA) carrying a large-scale deletion (ΔmtDNA), single point 
mutations in the tRNALys gene, and in the tRNALeu(UUR) gene causes CPEO (chronic 
progressive external ophthalmoplegia), MERRF (myoclonic epilepsy with ragged-red 
fibers), and MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and 
stroke-like episodes), respectively—the three most prevalent mitochondrial diseases (1-
3). However, there are slight differences among the three disease phenotypes, even 
though these pathogenic mtDNA mutations all induce mitochondrial respiration defects. 
Considering that mitochondrial respiratory function is controlled by both mitochondrial 
and nuclear genomes (1-3), this controversial issue can be clarified by generating 
transmitochondrial mice (‘mito-mice’) that share the same nuclear genetic background 
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but carry different pathogenic mtDNA mutations corresponding to the mutations found 
in the three prevalent mitochondrial diseases. However, no well-established effective 
protocols are available for introducing mutagenized mtDNA into the mitochondria of 
mammalian cells.  
In our previous studies (4-8), we found mtDNAs carrying pathogenic mutations in 
mouse cell lines, transferred them into mouse female germlines, and generated several 
types of mito-mice, including mito-mice-Δ (4, 5) which harbor ΔmtDNA and therefore 
are disease models for CPEO. However, mito-mice harboring mtDNA with pathogenic 
mutations in the tRNALys and tRNALeu(UUR) genes—and therefore prospective disease 
models of MERRF and MELAS, respectively—have not previously been established 
due to the unavailability of mouse cell lines with corresponding tRNA mutations in 
mtDNA. 
To complement the paucity of effective technologies required for introducing 
mutagenized mtDNA into mitochondria of living mouse cells, we here developed an 
alternative strategy involving cloning and sequence analysis to detect small amounts of 
mtDNA with somatic mutations in the mitochondrial tRNA genes. Because pathogenic 
mutations responsible for mitochondrial diseases occur preferentially in the tRNALeu(UUR) 
and tRNALys genes of humans (1-3), we sequenced 43 clones generated from PCR 
products carrying the mitochondrial tRNALeu(UUR) and tRNALys genes of P29 mouse lung 
carcinoma cells (9). One of the 43 clones had a somatic G7731A mutation in tRNALys, 
which enabled the generation of transmitochondrial mito-mice expressing respiration 
defects for their use as models for diseases caused by mutations in the mitochondrial 
tRNALys gene.  
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Results 
Cloning and sequence analysis of PCR products including tRNA genes 
To detect small proportion of mtDNA with somatic and possibly pathogenic mutations 
in the tRNALeu(UUR) and tRNALys genes, we used two sets of primers so that the resulting 
PCR products would include the tRNALeu(UUR) or tRNALys gene of P29 cells (Fig. S1). 
After cloning the PCR products, we sequenced all 43 clones obtained and compared the 
resulting sequences with that of mtDNA from P29 cells (Table 1). We found one and 
two somatic mutations in the mitochondrial tRNALeu(UUR) and tRNALys genes, 
respectively. Given that each somatic mutation was present in only one of the 43 clones, 
the proportion of each in the mtDNA population of P29 cells would be about 2.2%.  
The T7728C and G7731A mutations in the tRNALys gene both occurred in conserved 
sites (Table S1) and may correspond to pathogenic mutations that induce respiration 
defects by their accumulation. Moreover, an orthologous mutation to mouse G7731A 
has been reported to occur in human mtDNA from patients with mitochondrial diseases 
(10, 11).  
Therefore, we selected these mutations in mtDNA for the generation of mito-mice. In an 
attempt to detect the T7728C and G7731A mutations in P29 mtDNA, we performed 
Xmn I and Dra I digestions of the PCR products of mtDNA, because the T7728C and 
G7731A mutations create an Xmn I site and a Dra I site, respectively (see SI Materials 
and Methods). However, the T7728C and G7731A mutations were undetectable due to 
their insufficient amounts in P29 cells.  
Concentration of G7731A mtDNA in subclones of P29 cells 
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We previously showed that two mtDNA haplotypes with different mutations in single 
cells segregate stochastically during cell division (12). Therefore, some individual cells 
in the P29 population may possess detectable amounts of the mutated mtDNA. To 
obtain some individual cells that had accumulated either T7728C mtDNA or G7731A 
mtDNA from the P29 cell population, we isolated 100 subclones from P29 cells. Their 
mtDNA genotyping showed that two subclones, P29-42 and P29-69, possessed 34% and 
48% G7731A mtDNA, respectively. However, we did not obtain any subclones 
carrying detectable amounts of T7728C mtDNA. 
In the case of human mitochondrial tRNA gene mutations found in patients with 
mitochondrial diseases, respiration defects were apparent only when the mutated 
mtDNA had accumulated to more than 90% (13). To isolate P29 cells with more than 
90% G7731A mtDNA, we cultured subclone P29-69, which had 48% G7731A mtDNA, 
for additional 3 months to allow further amplification of G7731A mtDNA through 
stochastic segregation; we then isolated more than 200 subclones from the P29-69 cells. 
We obtained one subclone, P29-69-183, which contained 92% G7731A mtDNA (Fig. 
1A)—a level likely to be sufficient for the expression of respiration defects, if the 
G7731A mutation indeed is a pathogenic mutation.  
Determination of the pathogenicity of G7731A mtDNA  
Comparison of the O2 consumption rates between parental P29 cells and the P29-69-
183 cells revealed the expression of respiration defects in the P29-69-183 cells (Fig. 1B). 
Moreover, P29-69-183 cells demonstrated slight overproduction of reactive oxygen 
species (Fig. 1C), indicating the pathogenicity of the G7731A mutation. Whole-
sequence analysis of mtDNA in P29-69-183 cells showed that the G7731A mutation is 
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the only mutation in those cells that is capable of inducing respiration defects (Table 
S3). However, we had to resolve two important issues before generation of the mito-
mice carrying G7731A mtDNA.  
First, we had to confirm that the respiration defects in P29-69-183 cells were due to 
G7731A mtDNA and not to the selection of cells with mutations in nuclear DNA that 
were acquired during repeated recloning. Second, P29-69-183 cells could not be used as 
mtDNA donors to isolate mouse ES cells with G7731A mtDNA because of the 
difficulty of excluding unenucleated P29-69-183 cells from fusion mixtures of ES and 
enucleated P29-69-183 cells.  
To simultaneously resolve these issues, we cytoplasmically transferred G7731A 
mtDNA from P29-69-183 cells into mtDNA-less (ρ0) B82 cells (6). B82 cells are mouse 
fibrosarcoma cells that are resistant to 5-bromodeoxyuridine (BrdU) and sensitive to 
hypoxanthine–aminopterin–thymidine (HAT) due to their deficiency of thymidine 
kinase activity (6). Moreover, ρ0 B82 cells are unable to grow in the absence of uridine 
and pyruvate due to their complete lack of mtDNA. Using selection medium containing 
BrdU and lacking uridine and pyruvate, we isolated two colonies, B82mt7731-1 and -2. 
Genotyping of mtDNA showed that B82mt7731-1 and -2 possessed 70% and 95% 
G7731A mtDNA, respectively (Fig. 2A), indicating the transfer of G7731A mtDNA 
from P29-69-183 cells into ρ0 B82 cells.  
We then examined the respiratory function of these 2 cybrids by estimating O2 
consumption rates and the amounts of reactive oxygen species. The B82mt7731-2 
cybrids showed decreased O2 consumption rates (Fig. 2B) and increased production of 
reactive oxygen species (Fig. 2C) compared with those of B82mtB6 cybrids containing 
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normal mtDNA from B6 mice. Therefore, respiration defects were transferred to 
B82mt7731 cybrids concurrently with the transfer of G7731A mtDNA from P29-69-
183 cells into ρ0 B82 cells, suggesting that the somatic G7731A mutation in mtDNA is 
a pathogenic mutation that can induce mitochondrial respiration defects by its 
predominant accumulation. Furthermore, B82mt7731 cybrids are effective as donors of 
G7731A mtDNA to ES cells, because unenucleated B82mt7731 cybrids can be 
excluded by using selection medium containing HAT. 
Isolation of ES cells containing G7731A mtDNA and their chimeric mice 
Our previous study showed that no chimeric mice were obtained from ES cells carrying 
predominant amounts of ΔmtDNA, because the significant respiration defects induced 
by ΔmtDNA inhibited differentiation of ES cells to various tissues and germ cells (14). 
Therefore, we were concerned that the transfer of mtDNA from B82mt7731-2 cybrids 
containing 95% G7731A mtDNA to ES cells would inhibit generation of chimeric mice, 
and instead used B82mt7731-1 cybrids containing lower proportions of G7731A 
mtDNA (Fig. 2A) as mtDNA donors.  
Female (XO)-type ES cells (TT2 cells) were pretreated with rhodamine 6G (R6G) to 
eliminate endogenous mitochondria and mtDNA. They then were used as recipients of 
G7731A mtDNA and fused with enucleated B82mt7731-1 cybrids. The fusion mixture 
was cultured in selection medium containing HAT to exclude unenucleated 
B82mt7731-1 cybrids. Seven ES clones grew in the selective medium, two of which—
clones ESmt7731-4 and -7—contained G7731A mtDNA (Fig. S2). The absence of 
G7731A mtDNA in the remaining five clones may be due to incomplete elimination of 
endogenous mtDNA in ES cells during R6G pretreatment.  
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We then aggregated the ESmt7731-4 and -7 cybrid clones with 8-cell-stage mouse 
embryos (ICR strain) and obtained 35 F0 chimeric mice. Because mouse mtDNA is 
inherited strictly maternally (15, 16), we selected 15 F0 chimeric female mice with 
13%–76% G13997A mtDNA in their tails as founder mice (Table 2) and mated them 
with B6 male mice to generate F1 mice that carried G7731A mtDNA due to its transfer 
through the female germline.  
Generation of mito-mice-tRNALys7731 via female germ line transfer of G7731A mtDNA 
Of the 15 F0 female chimeras, 11 produced a total of 121 F1 pups, 63 of which had 
G7731A mtDNA in their tails (Table 2). This finding suggests that G7731A mtDNA 
was transmitted maternally from F0 female mice to F1 progeny. Mice that carried 
G7731A mtDNA derived from lung carcinoma P29 cells were named ‘mito-mice-
tRNALys7731’. Because the proportion of G7731A mtDNA did not differ significantly 
between tissues of the same F1 male mito-mouse-tRNALys7731 (Fig. S3), we can deduce 
the approximate overall proportion of G7731A mtDNA in mito-mice-tRNALys7731 by 
estimating the proportion of G7731A mtDNA in tail, which we can do without 
euthanizing them. 
Of the 63 F1 mice with G7731A mtDNA in their tails, seven F1 female mice carrying 
high proportions of G7731A mtDNA were mated with B6 male mice to obtain 
subsequent generations (F2-F5) of mito-mice-tRNALys7731 with sufficient G7731A 
mtDNA for the expression of respiration defects and resultant disorders. The 
proportions of G7731A mtDNA varied significantly among the pups born to each dam, 
but none of the pups carried more than 85% G7731A mtDNA (Fig. 3A). 
To examine the reasons for the lack of mito-mice-tRNALys7731 with more than 85% 
G7731A mtDNA, we estimated the proportion of G7731A mtDNA in the oocytes 
obtained by ovarian hyperstimulation of F5 female mito-mice-tRNALys7731 with high 
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proportions of G7731A mtDNA. The results again showed significant variation in 
G7731A mtDNA proportions among the oocytes and the absence of the oocytes with 
more than 85% G7731A mtDNA (Fig. 3B), indicating that lethality of oocytes with high 
levels of G7731A mtDNA is responsible for the absence of mito-mice-tRNALys7731 
carrying more than 85% G7731A mtDNA. 
Expression of disorders in mito-mice-tRNALys7731 with predominant G7731A mtDNA 
We used B6 mice as controls and three groups of F5 mito-mice-tRNALys7731 with 
different heteroplasmic conditions (low, intermediate, and high levels of G7731A 
mtDNA) in their tails to examine various phenotypes relevant to mitochondrial diseases 
(Fig. 4). 
First, we analyzed body length (Fig. 4A) and muscle strength (Fig. 4B), because 
abnormalities in these characteristics frequently occur in patients with mitochondrial 
diseases (10, 11), and these parameters can be examined without euthanizing the mice. 
Unlike mito-mice tRNALys7731 with low and intermediate levels, those with high levels 
of G7731A mtDNA showed short body length (Fig. 4A) and muscle weakness (Fig. 4B), 
which are closely associated with the clinical phenotypes caused by mutations in the 
mitochondrial tRNALys gene (2, 10, 11). 
We then quantitatively estimated mitochondrial respiratory function and revealed 
respiration defects in skeletal muscle and kidney from mito-mice-tRNALys7731 with high 
levels of G7731A mtDNA (Fig. 4C). Therefore, accumulation of G7731A mtDNA 
likely is responsible for the respiration defects in mito-mice-tRNALys7731 with high 
levels of G7731A mtDNA (Fig. 4C). These respiration defects in the skeletal muscle 
subsequently result in the expression of muscle weakness (Fig. 4B), which corresponds 
to a phenotype relevant to mitochondrial diseases (2). 
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In contrast, other metabolic parameters relevant to mitochondrial diseases were normal 
(Fig. S4). Histochemical analysis showed that ragged-red fibers (RRF) frequently 
observed in MERRF patients (2) and renal failures frequently observed in mito-mice-Δ 
(4, 5) were not found in mito-mice-tRNALys7731 (Figs. S5 and S6). Absence of these 
disorders in mito-mice-tRNALys7731 may be due in part to that G7731A mtDNA 
proportions in them were not sufficient to induce significant respiration defects. For 
example, G8344A mtDNA proportions exceed 85% in patients with MERRF (2). Our 
failure to obtain mito-mice-tRNALys7731 with more than 85% G7731A mtDNA can be 
explained by the lethality of mouse oocytes carrying these levels of G7731A mtDNA 
(Fig. 3B).  
These observations suggest that mito-mice-tRNALys7731 at least in part can serve as 
models to investigate pathogenesis of mitochondrial diseases that arise due to mutations 
in the mitochondrial tRNA genes. In addition, the transmission profiles of G7731A 
mtDNA showed that selecting oocytes with lower levels of the mutated mtDNA likely 
would be effective to prevent maternal transmission of the disease phenotypes to the 
progeny. 
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Discussion 
The current study generated mito-mice-tRNALys7731 carrying G7731A mtDNA with a 
pathogenic G7731A mutation in the mitochondrial tRNALys gene. Specifically, we 
concentrated a small proportion of mtDNA with a somatic G7731A mutation that was 
present in P29 cells and then introduced it into ES cells to generate mito-mice-
tRNALys7731. The resulting mice were used to investigate the pathogenesis and 
transmission profiles of G7731A mtDNA. 
Regarding the pathogenesis of G7731A mtDNA, mito-mice-tRNALys7731 with 74%-84% 
G7731A mtDNA demonstrated respiration defects and the resultant muscle weakness 
and short body length (Fig. 4). These abnormalities in our mice are very similar to those 
found in patients with mitochondrial diseases due to human orthologous G8328A 
mutation (10, 11) and in MERRF patients carrying the G8344A mutation in the tRNALys 
gene (2, 17-19). Although these abnormalities were expressed in mito-mice-tRNALys7731 
with 74%-84% G7731A mtDNA (Fig. 4) and in the patients with 57% (10) and 82% 
G8328A mtDNA (11), more than 85% G8344A mtDNA was required for the onset of 
severe abnormalities in patients with MERRF (2, 17-19). However, we could not obtain 
mito-mice-tRNALys7731 with more than 85% G7731A mtDNA (Fig. 3A), which would 
be expected to induce significant respiration defects and severe abnormalities 
corresponding to MERRF, owing to the lethality of mouse oocytes with more than 85% 
G7731A mtDNA (Fig. 3B). Therefore, the expression of the significant respiration 
defects and severe clinical disorders in MERRF patients can be explained by supposing 
the absence of lethality in human oocytes even at G8344A mtDNA levels exceeding 
85%. In contrast, our previous studies (4, 5) showed that mito-mice-Δ possessed more 
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than 85% ΔmtDNA with a large-scale deletion, and expressed significant respiration 
defects and severe abnormalities, even though their oocytes did not have more than 80% 
ΔmtDNA (20). The increase in the proportion of ΔmtDNA after birth may be due to its 
replication advantage (4, 5).  
The absence of abnormalities in mito-mice-tRNALys7731 with intermediate levels (37%-
56%) of G7731A mtDNA (Fig. 4A and B) appears to be different from what is observed 
for mtDNA with human orthologous G8328A mutation, because the patient with only 
57% G8328A mtDNA in the skeletal muscles expressed disorders (10). This apparent 
discrepancy may be due to the aging effects in the patient with 57% G8328A mtDNA, 
considering that the phenotypes of the mito-mice-tRNALys7731 were examined 4 months 
after the birth (Fig. 4), and that the patient expressed disorders 45 years after the birth 
(10). Thus, we have to examine whether mito-mice-tRNALys7731 with intermediate levels 
of G7731A mtDNA express abnormalities along with their aging. 
Regarding transmission profiles, those of mito-mice-tRNALys7731 are highly similar to 
those of MERRF patients, in that the mutated mtDNA is inherited to subsequent 
generations through the female germline, and the proportion of mutated mtDNA varied 
markedly among the pups born to each dam (Fig. 3A). The pups always carry wild-type 
mtDNA (Fig. 3A), due to the significant pathogenicity of G7731A mtDNA and 
resultant induction of oocyte lethality in the absence of wild-type mtDNA (Fig. 3B). In 
contrast, we previously generated mito-mice-COI6589 (6) and mito-mice-ND613997 (7, 8), 
which carry a 100% (homoplasmic) T6589C mtDNA mutation and a homoplasmic 
G13997A mtDNA mutation in the structural genes COXI and ND6, respectively, due to 
the mild pathogenicity of the mutations. Because patients with MERRF and mito-mice-
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tRNALys7731 always carry both wild-type mtDNA and mutated mtDNA, mito-mice-
tRNALys7731 are appropriate models for further investigating the transmission profiles of 
mutated mtDNA with marked pathogenicity. 
The heteroplasmic mtDNA (wild-type mtDNA and mutated G7731A mtDNA) of our 
mito-mice-tRNALys7731 segregated stochastically, like those derived from different 
mouse strains (BALB and NZB) with polymorphic mutations (21) and those with and 
without point mutations (22). The significant variation in the G7731A mtDNA 
proportions among pups (Fig. 3A) may reflect ‘bottleneck effects’ with (23, 24) or 
without decrease in the mtDNA copy number (25, 26) during female germline 
transmission of the heteroplasmic mtDNAs.  
Regarding primary prevention of mitochondrial diseases, the results in Figs. 3 and 4 
indicate that the selection of oocytes with low proportions of G7731A mtDNA likely 
would yield phenotypically normal mice. In contrast, our previous study (20) showed 
that nuclear transplantation from zygotes of transmitochondrial mito-mice-Δ into 
enucleated zygotes with normal mtDNA is effective as germline gene therapy. Many 
recent reports similarly have noted that the use of the nuclear transplantation from 
human oocytes of affected mothers into enucleated oocytes donated by unrelated 
women would prevent the transmission of mitochondrial diseases caused by mtDNA 
mutations to their children (27-29). However, this technology includes the risk of 
inducing nuclear abnormalities, even though it excludes the risk of mitochondrial 
abnormalities. This problem would be resolved by the selection of oocytes with low 
proportions of mutated mtDNA. Previous study showed that polar bodies are effective 
for preimplantation genetic diagnosis (PGD) to deduce the proportion of mutated 
15 
mtDNA in mouse oocytes (20). However, subsequent studies using polar bodies from 
human oocytes (30) and blastomeres from human embryos (31, 32) indicated that 
blastomeres are more appropriate than are polar bodies for PGD to deduce the 
proportion of mutated mtDNA. Although this procedure would not completely exclude 
the mutated mtDNA from the affected mothers, our previous studies (33, 34) showed 
the presence of inter-mitochondrial complementation to maintain normal respiratory 
function in the presence of the mutated mtDNA. Therefore, in light of the results in Figs. 
3 and 4, we propose that the selection of embryos with low proportions of mutated 
mtDNA from affected mothers would be effective for obtaining unaffected children. 
The risk of late-onset disorders in subjects with low proportions of mutated mtDNA 
appears to be negligible, because no subjects with less than 40% MERRF G8344A 
mutation in the blood expressed any abnormal symptoms throughout their lifetime (17). 
Moreover, mito-mice-COI6589 carrying homoplasmic T6589C mtDNA in the COX1 
gene and expressing mild respiration defects showed normal lifespans and no late-onset 
disorders (6, 8). Although mito-mice-ND613997 carrying homoplasmic G13997A 
mtDNA in the ND6 gene developed late-onset and age-related disorders (8), the onset 
was not due to respiration defects but to overproduction of reactive oxygen species, 
which can be suppressed by the administration of antioxidants (8). Because high 
proportions of G7731A mtDNA also induced slight overproduction of reactive oxygen 
species (Fig. 2C), we will examine whether mito-mice-tRNALys7731 with high 
proportions of G7731A mtDNA express late-onset disorders due to overproduction of 
reactive oxygen species.  
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Materials and Methods 
Cell lines and cell culture; Cloning and sequencing of PCR products; Genotyping of 
mtDNA; Isolation of B82mt7731 cybrids; Isolation of ESmt7731 cybrids; Generation of 
chimeric mice and mito-mice-tRNALys7731; Mice; Oxygen consumption; Measurement 
of reactive oxygen species in mitochondria ; Histopathologic analyses; Grip strength 
test; Biochemical measurements of respiratory enzyme activity; Measurement of blood 
glucose, lactate, and blood urea nitrogen (BUN); Measurement of hematocrit values; 
Sequence analysis; Statistical analysis. These are detailed in SI Materials and Methods. 
 
Acknowledgments 
This work was supported by Grants-in-Aid for Scientific Research A 25250011 (to J.-
I.H.), Scientific Research A 23240058 (to K.N.), and Scientific Research on Innovative 
Areas 24117503 (to J.-I.H.) from the Japan Society for the Promotion of Science. This 
work was supported also by the World Premier International Research Center Initiative; 
Ministry of Education, Culture, Sports, Science and Technology–Japan (to K.N. and J.-
I.H.). 
 
References 
1. Larsson N-G and Clayton DA (1995) Molecular genetic aspects of human 
mitochondrial disorders. Annu Rev Genetics 29:151-178. 
17 
2. Wallace DC (1999) Mitochondrial diseases in man and mouse. Science 
283(5407):1482-1488. 
3. Taylor RW and Turnbull DM (2005) Mitochondrial DNA mutations in human 
disease.  Nat Rev Genet 6(5):389-402. 
4. Inoue K, et al. (2000) Generation of mice with mitochondrial dysfunction by 
introducing mouse mtDNA carrying a deletion into zygotes. Nat Genet 26(2):176-181. 
5. Nakada K, et al. (2001) Inter-mitochondrial complementation: Mitochondria-specific 
system preventing mice from expression of disease phenotypes by mutant mtDNA. Nat 
Med 7(8):934-940. 
6. Kasahara A, et al. (2006) Generation of trans-mitochondrial mice carrying 
homoplasmic mtDNAs with a missense mutation in a structural gene using ES cells. 
Hum Mol Genet 15(6):871-881. 
7. Yokota M, et al. (2010) Generation of trans-mitochondrial mice carrying 
homoplasmic mtDNAs with a missense mutation in a structural gene using ES cells. 
FEBS Lett 584(18):3943-3948. 
8. Hashizume O, et al. (2012) Specific mitochondrial DNA mutation in mice regulate 
diabetes and lymphoma development.  Proc Natl Acad Sci USA 109(26):10528-1053. 
9. Ishikawa K, et al. (2008) ROS-generating mitochondrial DNA mutations can regulate 
tumor cell metastasis. Science 320(5876):661-664.  
10. Houshmand M, Lindberg C, Moslemi AR, Oldfors A and Holme E (1999) A novel 
heteroplasmic point mutation in the mitochondrial tRNA(Lys) gene in a sporadic case 
of mitochondrial encephalomyopathy: de novo mutation and no transmission to the 
offspring. Hum Mutat 13(3):203-209.  
18 
11. Blakely EL, et al. (2007) Sporadic myopathy and exercise intolerance associated 
with the mitochondrial 8328G>A tRNALys mutation. J Neurol 254(9):1283-1285. 
12. Hayashi J-I, Tagashira Y, Yoshida MC, Ajiro K and Sekiguchi T (1983) Two 
distinct types of mitochondrial DNA segregation in mouse-rat hybrid cells: stochastic 
segregation and chromosome-dependent segregation. Exp Cell Res 147(1):51-61. 
13. Chomyn A, et al. (1992) MELAS mutation in mtDNA binding site for transcription 
termination factor causes defects in protein synthesis and in respiration but no change in 
levels of upstream and downstream mature transcripts. Proc Natl Acad Sci USA 
89(10):4221-4225. 
14. Ishikawa K, et al. (2005) Application of ES cells for generation of respiration-
deficient mice carrying mtDNA with a large-scale deletion. Biochem Biophys Res 
Commun 333(2):590-595. 
15. Kaneda H, et al. (1995) Elimination of paternal mitochondrial DNA in intraspecific 
crosses during early mouse embryogenesis. Proc Natl Acad Sci USA 92(10):4542-4546. 
16. Shitara H, Hayashi J-I, Takahama S, Kaneda H, and Yonekawa H (1998) Maternal 
inheritance of mouse mtDNA in interspecific hybrids: segregation of the leaked paternal 
mtDNA followed by the prevention of subsequent paternal leakage. Genetics 
148(2):851-857. 
17. Hammans SR, et al. (1993) The mitochondrial DNA transfer RNALys A → G(8344) 
mutation and the syndrome of myoclonic epilepsy with ragged red fibres (MERRF). 
Brain 116( Pt 3):617-632. 
18. Hammans SR, et al. (1995) The mitochondrial DNA transfer RNALeu(UUR) A → 
G(3243) mutation. A clinical and genetic study. Brain 118 ( Pt 3):721-734. 
19 
19. Chinnery P, Howell N, Lightowlers RN, and Turnbull DM (1998) MELAS and 
MEFFR: The relationship between maternal mutation load and the frequency of 
clinically affected offspring. Brain 121( Pt 10):1889-1894. 
20. Sato A, et al. (2005) Gene therapy for progeny of mito-mice carrying pathogenic 
mtDNA by nuclear transplantation. Proc Natl Acad Sci USA 102(46):16765-16770. 
21. Jenuth JP, Peterson AC, Fu K, Shoubridge EA (1996) Random genetic drift in the 
female germline explains the rapid segregation of mammalian mitochondrial DNA. Nat 
Genet 14(2):146-151. 
22. Freyer C, et al. (2012) Variation in germline mtDNA heteroplasmy is determined 
prenatally but modified during subsequent transmission. Nat Genet 44(11): 1282-1285. 
23. Cree LM, et al. (2008) A reduction of mitochondrial DNA molecules during 
embryogenesis explains the rapid segregation of genotypes. Nat Genet 40(2):249-254. 
24. Wai T, Teoli D and Shoubridge EA (2008) The mitochondrial DNA genetic 
bottleneck results from replication of a subpopulation of genomes. Nat Genet 40(12): 
1484-1488. 
25. Cao L, et al. (2007) The mitochondrial bottleneck occurs without reduction of 
mtDNA content in female mouse germ cells. Nat Genet 39(3):386-390. 
26. Cao L, et al. (2009) New evidence confirms that the mitochondrial bottleneck is 
generated without reduction of mitochondrial DNA content in early primordial germ 
cells of mice. PLoS Genet 5(12): e1000756. 
27. Craven L, et al. (2010) Pronuclear transfer in human embryos to prevent 
transmission of mitochondrial DNA diseases. Nature 465(7294):82-85. 
20 
28. Tachibana M, et al. (2013) Towards germline gene therapy of inherited 
mitochondrial diseases. Nature 493(7434):627-631. 
29. Paull D, et al. (2013) Nuclear genome transfer in human oocytes eliminates 
mitochondrial DNA variants. Nature 493(7434):632-637. 
30. Gigarel N, et al. (2011) Poor correlations in the levels of pathogenic mitochondrial 
DNA mutations in polar bodies versus oocytes and blastomeres in humans. Am J Hum 
Genet 88(4):494-498. 
31. Steffann J, et al. (2006) Analysis of mtDNA variant segregation during early human 
embryonic development: a tool for successful NARP preimplantation diagnosis. J Med 
Genet 43(3):244-247. 
32. Tajima H, et al. (2007) The development of novel quantification assay for 
mitochondrial DNA heteroplasmy aimed at preimplantation genetic diagnosis of Leigh 
encephalopathy. J Assist Reprod Genet 24(6):227-232. 
33. Hayashi J-I, Takemitsu M, Goto Y-i and Nonaka I (1994) Human mitochondria and 
mitochondrial genome function as a single dynamic cellular unit. J Cell Biol 125(1):43-
50. 
34. Ono T, Isobe K, Nakada K and Hayashi J-I (2001) Human cells are protected from 
mitochondrial dysfunction by complementation of DNA products in fused mitochondria. 
Nat Genet 28(3):272-275. 
 
Figure legends 
Fig. 1 Characterization of P29-69-183 cells to determine the pathogenicity of a G7731A 
mutation in the mitochondrial tRNALys gene. (A) Estimation of the proportion of 
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G7731A mtDNA in P29 and P29-69-183 cells by Dra I digestion of the PCR products. 
The G7731A mtDNA produced 96-bp and 34-bp fragments due to the gain of a DraI 
site through G7731A substitution in the tRNALys gene, whereas mtDNA without the 
mutation produced a 130-bp fragment. Quantitative estimation of G7731A mtDNA 
showed that P29-69-183 cells contained 92% G7731A mtDNA. (B) Estimation of O2 
consumption rates of P29 and P29-69-183 cells. *, P < 0.05. (C) Estimation of 
mitochondrial superoxide levels in P29 and P29-69-183 cells after their treatment with 
MitoSOX Red. **, P < 0.01. 
Fig. 2 Characterization of transmitochondrial B82mt7731 cybrids for their use as 
G7731A mtDNA donors to ES cells. (A) Estimation of the proportion of G7731A 
mtDNA in cybrids clones B82mt7731-1 and B82mt7731-2 by Dra I digestion of the 
PCR products. Quantitative estimation of G7731A mtDNA showed that B82mt7731-1 
and B82mt7731-2 had 70% and 95% G7731A mtDNA, respectively. (B) Estimation of 
O2 consumption rates. **, P < 0.01. (C) Estimation of mitochondrial superoxide levels 
after treatment with MitoSOX Red. **, P < 0.01. 
Fig. 3 Variation of G7731A mtDNA proportions among pups or oocytes from 
individual female mice. (A) Variation of G7731A mtDNA proportions among F5 pups 
born to three F4 dams. G7731A mtDNA proportions were estimated by using tails from 
F5 pups that were obtained from three F4 dams with high proportions of G7731A 
mtDNA. (B) Variation of G7731A mtDNA proportions among oocytes obtained from 
three F5 female mice. G7731A mtDNA proportions were estimated by using oocytes 
obtained by ovarian hyperstimulation of F5 female mito-mice-tRNALys7731 with high 
proportions of G7731A mtDNA. 
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Fig. 4 Characterization of F5 male mito-mice-tRNALys7731 according to phenotypes 
associated with mitochondrial diseases. Comparison of (A) body length and (B) muscle 
(grip) strength between B6 mice (n=3) and F5 mito-mice-tRNALys7731 carrying low 
(13%–15%; n = 3), intermediate (37%–56%; n = 3), and high (76%–84%; n = 3) 
proportions of G7731A mtDNA. Body length and grip strength were measured at 4 
months after birth. Data are presented as means ± SD. *, P < 0.05; **, P < 0.01. (C) 
Comparison of activities of mitochondrial respiratory complexes (I+III, II+III, and IV) 
between B6 mice and F5 mito-mice-tRNALys7731 carrying high proportions (76–84%) of 
G7731A mtDNA in the skeletal muscle and the kidney at 4 months after birth. 
Respiratory complex I (NADH dehydrogenase), complex II (succinate dehydrogenase), 
complex III (cytochrome c reductase), and complex IV (cytochrome c oxidase) are 
components of the electron-transport chain. Enhanced activity of complex II+III in 
mito-mice-tRNALys7731 would be due to compensatory activation of complex II, which 
is controlled exclusively by nuclear DNA. Data are presented as means ± SD (n = 3). *, 
P < 0.05; **, P < 0.01. 
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Table 1 Somatic mutations in P29 mtDNA according to cloning and sequence analysis of the PCR products including the tRNALeu(UUR) and 
tRNALys genes 
 
No. of clones 
tRNA genes LeuUUR Ile Met SerCUN Lys Lys 
nucleotide position 2721 3760 3883 6931 7728† 7731‡ 
P29 sequence* T G - T T G 
1   del - - - - - 
1 
 
- A - - - - 
1 
 
- - insA - - - 
1 
 
- - - C - - 
1 
 
- - - - C - 
1 
 
- - - - - A 
37   - - - - - - 
 
* Registered under the GenBank accession number EU312160. 
† The T7728C mutation in the tRNALys gene occurred in a site highly conserved throughout animals and fungi (see Table 2). The mutation 
affects the first base of an anticodon triplet (TTT), resulting in an anticodon swap from TTT to CTT (Lys to Glu). 
‡ The mutation equivalent to the G7731A mutation in the tRNALys gene of mice has been reported to occur in the mtDNA from human 
patients with mitochondrial diseases (10, 11). 
 
Table 2 Generation of F0 chimeric mice and their F1 progeny that carry G7731A mtDNA in their tails. 
 
 
 
 
 
 
 
 
 
 
 
* Chimerism was judged by coat color. 
 
ES clones 
 
% G7731A  
mtDNA 
15 F0 chimeric female mice   F1 mice 
 
% Chimerism* 
 % G7731A 
mtDNA 
 in tails    
No. of F1 pups with 
G7731A mtDNA / No. 
of F1 pups 
ESmt7731-4  49.8 95  68   4/4  
   95  53   2/12  
   90  45   24/24  
   50  48   0/17  
   40  16   0/0  
   35  21   0/8  
ESmt7731-7  48.8 95  72   19/19  
   95  76   4/4  
   95  72   2/12  
   95  68   8/8  
   80  52   0/8  
   60  61    0/5  
   40  26   0/0  
   15  13   0/0  
   10  19   0/0  
          Total 63/121   
SI Figure Legends 
Fig. S1 Nucleotide positions of PCR primers on the mouse mtDNA map. To detect 
small proportions of mtDNA with somatic but possibly pathogenic mutations in the 
tRNALeu(UUR) and tRNALys genes of P29 cells, we used two sets of PCR primers so that 
the resultant PCR products included the tRNALeu(UUR) and tRNALys genes, respectively. 
These products also included five additional tRNA genes (tRNAIle, tRNAGln, tRNAMet, 
tRNASer(CUN), and tRNAAsp).  
Fig. S2 Identification of G7731A mtDNA in ESmt7731 cybrid clones grown in 
selection medium. We were able to obtain two ESmt7731 cybrid clones carrying 
G7731A mtDNA (ESmt7731-4 and -7) but were unable to exclude ES cells that lacked 
G7731A mtDNA, owing to incomplete elimination of endogenous mtDNA by R6G 
treatment. Accordingly, ESmt7731-1, -2, -3, -5, and -6 correspond to ES cells that 
lacked G7731A mtDNA but contained endogenous mtDNA. 
Fig. S3 Proportions of G7731A mtDNA in the tissues from a single F1 male mouse. 
Note that the proportion of G7731A mtDNA did not differ significantly among different 
tissues from the same F1 male mito-mice-tRNALys7731, suggesting that we can deduce 
the overall proportion of G7731A mtDNA in mito-mice-tRNALys7731 from that in the tail 
without euthanizing mice. 
Fig. S4 Analyses of metabolic parameters related to mitochondrial diseases by using 
peripheral blood from mito-mice-tRNALys7731 with high proportions of G7731A mtDNA. 
(A) Blood urea nitrogen. (B) Hematocrit. (C) Blood glucose levels before and after 
glucose administration. (D) Blood lactate levels before and after glucose administration. 
No statistically significant differences between B6 and mito-mice-tRNALys7731 with high 
SIText
proportions of G7731A mtDNA were obtained. Data are presented as mean ± SD (n = 
3).  
Fig. S5 Histopathologic analysis to identify ragged red fibers (RRF) in skeletal muscle. 
Cryosections (thickness, 10 µm) of skeletal muscle were stained by using modified 
Gomori trichrome for histopathologic analysis to identify RRF. No RRF were present in 
mito-mice-tRNALys7731 with high proportions of G7731A mtDNA. Bar, 50 μm. 
Fig. S6 Morphology and histopathologic analysis of kidney. (A) Morphology of kidneys 
from B6 mice (left) and mito-mice-tRNALys7731 with 76% G7731A mtDNA (right). Bar, 
1 cm. (B) Histopathology of the renal cortex of kidneys from B6 mice (left) and 
mito-mice-tRNALys7731 with 76% G7731A mtDNA (right). Formalin-fixed, 
paraffin-embedded sections (thickness, 5 μm) were stained with hematoxylin and eosin. 
No renal failure was noted in mito-mice-tRNALys7731. Bar, 50 μm. 
Sl Materials and Methods 
Cell lines and cell culture. Mouse P29 cells, their subclones, mtDNA-less (ρ0) B82 
cells, and their transmitochondrial cybrid clones were grown in DMEM 
(Sigma-Aldrich) containing 10% fetal calf serum, uridine (50 ng/ml), and pyruvate (100 
ng/ml). Mouse ES cells (TT2-F, an XO subline established from XY TT2 cells; Riken 
BioResource Center) and transmitochondrial ES cybrids were cultivated on 
mitomycin-C–inactivated feeder cells derived from fetal fibroblasts in DMEM 
(Invitrogen) supplemented with 15% Knockout Serum Replacement (Invitrogen), 
non-essential amino acids (MP Biomedicals LLC), leukemia inhibitory factor (105 U/ml, 
Invitrogen), and 100 μM 2-mercaptoethanol (Sigma–Aldrich). 
Cloning and sequencing of PCR products. Total DNA extracted from P29 cells was 
used as the template for PCR amplifications, which generated two mtDNA fragments, 
F1 and F2, by using unique primer pairs that were designed to generate 2.6- and 2.7-kb 
fragments, respectively. The sequences of the primers were based on the standard 
mtDNA sequence of B6 mice (GenBank accession no., AY172335): F1 forward, 
nucleotides 2045–2064; F1 reverse, 4623–4603; F2 forward, 5931–5950; and F2 
reverse, 8626–8606 (Fig. S1). All PCR amplifications were performed in 50 µl of 
solution consisting of PCR buffer, 0.2 mM dNTPs, 0.6 mM primers, 1 U AmpliTaq 
Gold DNA polymerase (Perkin-Elmer Applied Biosystems), and 1 µg of cellular DNA 
as template. Reaction conditions were 95 ºC for 10 min, followed by 35 cycles of 60 s at 
95 ºC, 60 s at 50–56 ºC, and 150 s at 72 ºC. PCR products were ligated into pUC118 
(Takara) and then introduced into DH5α cells (Takara). Sequence templates were 
prepared by using a TempliPhi DNA Sequencing Template Amplification Kit 
(Amersham Pharmacia Biosciences) according to the manufacturer’s protocol. 
Sequence reactions were performed by using dye termination methods (Takara PCR 
Thermal Cycler GP), and samples were sequenced on a MegaBACE1000 automated 
sequencer (Amersham Pharmacia Biosciences). 
Genotyping of mtDNA. To detect the T7728C mutation, a 71-bp fragment containing 
the 7728 site was PCR-amplified by using the nucleotide sequences 7703 to 7723 
(5′-TATGAAGCTAAGAGCGgaAAC-3′, small letters indicate mismatch) and 7773 to 
7754 (5′-TGTGGCATATCACTATGGAG-3′) as oligonucleotide primers. Combination 
of the PCR-generated mutation with the T7728C mutation creates a restriction site for 
Xmn I and generates 50- and 21-bp fragments on Xmn I digestion of the PCR products. 
To detect the G7731A mutation, a 130-bp fragment containing the 7731 site was 
PCR-amplified by using the nucleotide sequences from 7633 to 7653 
(5′-GCCCATTGTCCTAGAAATGGT-3′) and 7762 to 7732 
(5′-ACTATGGAGATTTTAAGGTCTCTAACTTTAA-3′) as oligonucleotide primers. 
The G7731A mutation creates a restriction site for Dra I and generates 96- and 34-bp 
fragments on Dra I digestion of PCR products. The restriction fragments were separated 
by electrophoresis in a 3% agarose gel. For quantification of G7731A mtDNA, we used 
the NIH Image program. 
Isolation of B82mt7731 cybrids. We used mtDNA-less (ρ0) B82 cells as recipients for 
G7731A mtDNA. ρ0 B82 cells are resistant to BrdU and sensitive to HAT due to their 
deficiency of thymidine kinase activity. Furthermore, ρ0 B82 cells are unable to grow in 
the absence of uridine and pyruvate due to their absence of mtDNA. mtDNA donor 
P29-69-183 cells were pretreated with cytochalasin B (10 μg/ml) for 10 min and 
centrifuged at 7,500 × g for 10 min at 37 °C for enucleation; the resultant cytoplasts 
were fused with ρ0 B82 cells by using polyethylene glycol. The fusion mixture was 
cultured in selection medium containing BrdU (30 µg/ml) and lacking uridine and 
pyruvate. The selection medium excluded unenucleated P29-69-183 cells and unfused 
ρ0 B82 and thus allowed exclusive growth of transmitochondrial B82mt7731 cybrids. 
Isolation of ESmt7731 cybrids. Host ES cells were pretreated with rhodamine 6G 
(R6G; 0.38–1.5 μg/ml in 3% ethanol) for 48 h to eliminate endogenous mitochondria 
and mtDNA (1, 2). The ES cells then were washed with PBS and suspended in 
R6G-free medium for 2 h to allow recovery. mtDNA donor B82mt7731 cybrids were 
pretreated with cytochalasin B (10 μg/ml) for 10 min and centrifuged at 22,500 × g for 
30 min at 37 °C for enucleation. The resultant cytoplasts were fused with 
R6G-pretreated ES cells by using polyethylene glycol, and the fusion mixture was 
cultured in selection medium containing HAT to exclude unenucleated B82mt7731 
cybrids. At 7 days after fusion, growing colonies were harvested for mtDNA 
genotyping. Under these selection conditions, ES cells containing recovered 
endogenous mtDNA were not eliminated completely, owing to insufficient R6G 
treatment. 
Generation of chimeric mice and mito-mice-tRNALys7731. Frozen 8-cell-stage 
embryos of ICR mice (ARK Resource Company) were thawed, and their zona 
pellucidae were removed by treatment with acidified Tyrode’s buffer (Sigma–Aldrich). 
Each treated embryo was placed with about 50 ESmt7731 cybrids in a well of a 35-mm 
culture dish and incubated overnight to enable aggregation. The next day, the embryos 
were transferred into pseudopregnant ICR female mice (Japan SLC). The resulting 
progeny were identified by their coat-color chimerism. Founder (F0) chimeric female 
mice were mated with C57BL/6 J (B6; CLEA Japan) male mice to produce the F1 
generation, and F1 female mice with G7731A mtDNA in their tails (F1 female 
mito-mice-tRNALys7731) were backcrossed with B6 male mice to obtain F2 
mito-mice-tRNALys7731.  
Mice. Inbred B6 mice generated through more than 40 rounds of brother–sister mating 
were obtained from CLEA Japan. We maintained mito-mice-tRNALys7731 by repeated 
backcrossing of these female mice with B6 male mice. Animal experiments were 
performed in accordance with protocols approved by the Experimental Animal 
Committee of the University of Tsukuba, Japan (approval number, 12070).  
Oxygen consumption. Cells were washed once in PBS and then resuspended in PBS at 
a density of 4 × 106 cells/ml. Oxygen consumption was measured by using an oxygraph 
equipped with a Clark-type electrode (model 5300, Yellow Springs Instruments 
Company) at 37 °C. The cell suspension (2 ml) was transferred to a polarographic cell, 
and basal respiration was measured immediately under constant stirring. 
Measurement of reactive oxygen species in mitochondria. Reactive oxygen species 
were detected by using the mitochondrial superoxide indicator MitoSOX-Red 
(Invitrogen). Cells were incubated with 1 mM MitoSOX-Red for 15 min at 37 °C in 
PBS, washed twice with PBS, and then immediately analyzed by using flow cytometry 
(FACScan, Becton Dickinson). 
Histopathologic analyses. Formalin-fixed, paraffin-embedded sections (thickness, 5 
µm) were stained with hematoxylin and eosin to identify cases of renal failure. 
Cryosections (thickness, 10 µm) of skeletal muscle were stained by using a modified 
Gomori trichrome to identify RRF. 
Grip strength test. Muscle strength was estimated by using a Grip Strength Meter 
(Columbus Instruments); three sequential trials were performed on each mouse. 
Biochemical measurements of respiratory enzyme activity. Mitochondrial 
respiratory complex I (NADH dehydrogenase), complex II (succinate dehydrogenase), 
and complex III (cytochrome c reductase) are components of the electron-transport 
chain and are located in the mitochondrial inner membrane. The activity of these 
enzymes was assayed as described previously (4). Briefly, to estimate the activity due to 
complex I + III, NADH and cytochrome c (oxidized form) were used as substrates, and 
the reduction in cytochrome c was monitored by measuring absorbance at a wavelength 
of 550 nm. To estimate the activity due to complex II + III, sodium succinate and 
cytochrome c (oxidized form) were used as substrates, and the reduction of cytochrome 
c was monitored as described previously.  
Measurement of blood glucose, lactate, and blood urea nitrogen (BUN). To 
determine fasting blood lactate and glucose concentrations, peripheral blood was 
collected from the tail veins of mice after overnight fasting from food. After oral 
administration of glucose (1.5 g/kg body weight), blood was collected again, and lactate 
and glucose concentrations were measured by using an automatic blood lactate test 
meter (Lactate Pro; Arkray) and glucose test meter (Dexter ZII; Bayer), respectively. 
BUN was measured by using a Urea N B test (Wako Pure Chemical, Osaka, Japan) in 
accordance with the manufacturer's protocol. 
Measurement of hematocrit values. To determine hematocrit levels, capillary blood 
was collected from each mouse into heparinized capillary tubes and centrifuged at 
10,500 × g for 5 min. Packed cell volumes were measured by using a hematocrit reader. 
Sequence analysis. Each DNA (3 µg) extracted from P29-69-183 cells and from kidney 
of mito-mouse-tRNALys7731 were used to prepare the sequencing libraries. These 
sequencing libraries were constructed by using the TruSeq DNA LT Sample Prep Kit 
(Illumina) according to the instructions in TruSeq DNA Sample Preparation Guide Rev. 
C (Illumina). These sample DNA were sheared by using an acoustic solubilizer 
(Covaris), and the overhangs resulting from the fragmentation were converted to blunt 
ends by phosphorylation of the DNA fragments. The blunt fragments were adenylated at 
their 3ʹ ends were ligated to the ends of the DNA fragments, which were subsequently 
enriched by PCR. Clonal template clusters were generated from the sequencing library, 
and sequencing was performed by the reversible terminator-based method (5). Base 
calling and data conversion into Fastq files were performed by using software providing 
the Burrows-Wheeler Alignment Tool (6). 
Statistical analysis. Data are presented as means ± SD and were analyzed by using 
Student’s t test; P values less than 0.05 were considered significant.  
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Table S1 Comparison of mutations in the mouse mitochondrial tRNA gene with 
the wild-type tRNA genes of other species 
Comparison of mutations in the mouse mitochondrial tRNA 
gene with the wild-type tRNA genes of other species 
Leu(UUR) Lys 
del2721T T7728C G7731A 
Mutation ― C A 
Mouse T T G 
Human C T G 
Xenopus T T G 
Zebrafish C T G 
Drosophila T T A 
Nematoda ― T T 
Yeast C T G 
The GenBank accession numbers of the sequences used in the alignment are: mouse, AY172335; human, NC_012920; 
Xenopus, NC_001573; zebrafish, NC_002333; Drosophila, NC001709; Nematoda, NC_001328; yeast, NC_001224.
SITable1
Table S2 Whole-sequence analysis of the mtDNA from P29-69-183 cells
Whole-sequence analysis of the mtDNA from P29-69-183 cells 
genes tRNALys tRNAArg D-loop 
nucleotide position 7731 9818~ 9821~ 16099 16105 
P29 sequence* G (T)3 (A)9 (A)9 A T 
variant sequence A (T)2 (A)8 (A)10 C C 
 P29-69-183** 89.6%† 16.4% 8.2% 6.5% 31.6% 47.6% 
 mito-mouse-tRNALys7731‡ 80.0% 3.6% 0.5% 18.1% 26.9% 37.0% 
* P29 mtDNA sequence, GenBank accession number EU312160.
† Whole-sequence analysis of mtDNA from P29-69-183 cells showed that they had 89.6% G7731A mtDNA. This value 
was almost equivalent to that obtained in Fig. 1A (92%), suggesting the reliability of our quantification of G7731A mtDNA 
proportion by using restriction fragment length polymorphism. 
‡Kidney of F5 mito-mouse-tRNALys7731 possessing 81.3% G7731A mtDNA quantified by using restriction fragment length 
polymorphism was used for whole-sequence analysis of the mtDNA. All polymorphic mutations found in mtDNA of 
P29-69-183 cells have persisted in mtDNA of a mito-mouse-tRNA Lys7731. Registered under GenBank accession no. 
AP014541. 
**Registered under GenBank accession no. AP014540. 
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